Paulus Kirchhof

Paulus Kirchhof

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2016 in European Heart Journal
Verified
Journal Article
Closed access
PKPaulus Kirchhof
Paulus Kirchhof
SBStefano Benussi
Stefano Benussi
DKDipak Kotecha
Dipak Kotecha
AAAnders Ahlsson
Anders Ahlsson
DADan Atar
Dan Atar
KZKatja Zeppenfeld
Katja Zeppenfeld

1 July 2013 in Journal Of Hypertension
Verified
Journal Article
Open access
GMGiuseppe Mancia
Giuseppe Mancia
RFRobert Fagard
Robert Fagard
KNKrzysztof Narkiewicz
Krzysztof Narkiewicz
JRJosep Redon
Josep Redon
AZAlberto Zanchetti
Alberto Zanchetti
FZFaiez Zannad
Faiez Zannad
Because of new evidence on several diagnostic and therapeutic aspects of hypertension, the present guidelines differ in many respects from the previous ones. Some of the most important differences are listed below: 1. Epidemiological data on hypertension and BP control in Europe. 2. Strengthening of the prognostic value of home blood pressure monitoring (HBPM) and of its role for diagnosis and management of hypertension, next to ambulatory blood pressure monitoring (ABPM). 3. Update of the prognostic significance of night-time BP, white-coat hypertension and masked hypertension. 4. Re-emphasis on integration of BP, cardiovascular (CV) risk factors, asymptomatic organ damage (OD) and clinical complications for total CV risk assessment. 5. Update of the prognostic significance of asymptomatic OD, including heart, blood vessels, kidney, eye and brain. 6. Reconsideration of the risk of overweight and target body mass index (BMI) in hypertension. 7. Hypertension in young people. 8. Initiation of antihypertensive treatment. More evidence-based criteria and no drug treatment of high normal BP. 9. Target BP for treatment. More evidence-based criteria and unified target systolic blood pressure (SBP) (<140 mmHg) in both higher and lower CV risk patients. 10. Liberal approach to initial monotherapy, without any all-ranking purpose. 11. Revised schema for priorital two-drug combinations. 12. New therapeutic algorithms for achieving target BP. 13. Extended section on therapeutic strategies in special conditions. 14. Revised recommendations on treatment of hypertension in the elderly. 15. Drug treatment of octogenarians. 16. Special attention to resistant hypertension and new treatment approaches. 17. Increased attention to OD-guided therapy. 18. New approaches to chronic management of hypertensive diseas

29 August 2010 in European Heart Journal
Verified
Journal Article
Open access
PDF file
EAEuropean Heart Rhythm Association
European Heart Rhythm Association
ESEuropean Association for Cardio-Thoracic Surgery
European Association for Cardio-Thoracic Surgery
ACA John Camm
A John Camm
PKPaulus Kirchhof
Paulus Kirchhof
GLGregory Y H Lip
Gregory Y H Lip
FRFrans H Rutten
Frans H Rutten
Guidelines summarize and evaluate all currently available evidence on a particular issue with the aim of assisting physicians in selecting the best management strategy for an individual patient suffering from a given condition, taking into account the impact on outcome, as well as the risk–benefit ratio of particular diagnostic or therapeutic means. Guidelines are no substitutes for textbooks. The legal implications of medical guidelines have been discussed previously.

29 August 2014 in European Heart Journal
Verified
Journal Article
Open access
PDF file
RERaimund Erbel
Raimund Erbel
VAVictor Aboyans
Victor Aboyans
CBCatherine Boileau
Catherine Boileau
EBEduardo Bossone
Eduardo Bossone
RBRoberto Di Bartolomeo
Roberto Di Bartolomeo
IKIvan Kravchenko
Ivan Kravchenko
Guidelines summarize and evaluate all available evidence at the time of the writing process, on a particular issue with the aim of assisting health professionals in selecting the best management strategies for an individual patient, with a given condition, taking into account the impact on outcome, as well as the risk-benefit-ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help the health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

29 August 2014 in European Heart Journal
Verified
Journal Article
Open access
SWStephan Windecker
Stephan Windecker
PKPhilippe Kolh
Philippe Kolh
FAFernando Alfonso
Fernando Alfonso
JCJean-Philippe Collet
Jean-Philippe Collet
JCJochen Cremer
Jochen Cremer
JDJohn Davies
John Davies

29 August 2014 in European Heart Journal
Verified
Journal Article
Open access
PDF file
Perry ElliottPerry Elliott
Perry Elliott
AAAris Anastasakis
Aris Anastasakis
MBMichael Borger
Michael Borger
MBMartin Borggrefe
Martin Borggrefe
FCFranco Cecchi
Franco Cecchi
NSNeha Sekhri
Neha Sekhri
Guidelines summarize and evaluate all available evidence at the time of the writing process, on a particular issue with the aim of assisting health professionals in selecting the best management strategies for an individual patient, with a given condition, taking into account the impact on outcome, as well as the risk-benefit-ratio of particular diagnostic or therapeutic means. Guidelines and recommendations should help the health professionals to make decisions in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.